Beyond Air shares surge 11.29% on $32M financing deal, extended cash runway to 2027

The share price rose to its highest level so far this month, with an intraday gain of 11.29%.

Beyond Air’s surge followed a $32 million financing agreement with Streeterville Capital announced on November 5. The deal includes a $12 million promissory note with a 15% annual interest rate and a 24-month maturity, alongside a $20 million equity line of credit (ELOC). The promissory note’s deferred payment structure—no obligations for the first 12 months—provides immediate liquidity, while the ELOC allows the company to draw funds over 24 months based on market conditions. Proceeds will fund commercial expansion, including the FDA-approved LungFit PH device, and support clinical development of next-generation therapies targeting respiratory, neurological, and oncological conditions.

Chief Executive Steve Lisi emphasized the financing’s role in extending Beyond Air’s cash runway to 2027 and accelerating revenue growth through the LungFit PH product line. The company’s $22.9 million in pro forma cash as of September 30, 2025, combined with the new funding, positions it to advance trials for NO-based treatments in autism and solid tumors. The CEO also highlighted a 2026 profitability target, driven by recurring hospital-based revenue and potential home-use applications for chronic lung infections. The deal’s risk-mitigated terms—deferred payments and conditional equity access—have bolstered investor confidence, with shares rising 10.2% pre-market before closing up 1.08%.